Aktienanalyse zu Aligos Therapeutics, Inc. (ALGS)ALGSAligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Aligos Therapeutics Inc is a good buy right now due to its current price of $4.05, which is significantly below its 52-week high of $13.69, indicating potential upside. The company has recently secured a $25 million license deal and has a promising pipeline, with a projected trajectory indicating a potential increase of 369% based on historical patterns. However, the main risk is its recent earnings report showing a loss of $3.04 per share, which was a 25.1% surprise from the estimated loss of $2.43.